Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Engineered T cells prevent recurrence over five years.
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
Iceland and Georgia both have instigated aggressive testing and treatment initiatives.
Primary care physicians and ob-gyns are the top clinicians ordering such tests.
The World Health Organization wants to see 90 percent of the world’s population screened for hepatitis C by 2030.
But only a small fraction of those living with the virus worldwide have been cured.
In a recent study of more than 600 HIV-positive adults, 93 percent were cured of hep C.
Adding internal radiation or TACE did appear to help certain people, however.
The drug has already advanced to a Phase IIa trial.
Researchers examined the effects of an agent known as RO7049389 among people with and without hepatitis B.
The costs rise particularly steeply for those who quickly progress to end-stage liver disease.
This is according to a recent mathematical modeling study.
A European liver transplant registry saw a decline in hep C as a cause of needing a transplant.
Sovaldi (sofosbuvir) plus the new hep C drug ravidasvir cured 97 percent of those with a range of genotypes in a recent study.
About one third of those in a global study of individuals hospitalized with cirrhosis had such infections.
More hepatitis research from the 2018 International Liver Congress.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.